Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1724088

USP

Zanamivir

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H20N4O7
Numéro CAS:
139110-80-8
Poids moléculaire :
332.31
Numéro MDL:
MFCD00866966
Code UNSPSC :
41116107
ID de substance PubChem :
329751520
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

zanamivir

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

Clé InChI

ARAIBEBZBOPLMB-UFGQHTETSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Zanamivir USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Actions biochimiques/physiologiques

Zanamivir is an influenza viral neuraminidase inhibitor.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H315,H319,H335

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Ribavirin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1700

Ribavirin

Mupirocine United States Pharmacopeia (USP) Reference Standard

USP

1448901

Mupirocine

Tobramycine United States Pharmacopeia (USP) Reference Standard

USP

1667508

Tobramycine

N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid ≥93% (TLC)

Sigma-Aldrich

D9050

N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid

Ribavirin antiviral

Sigma-Aldrich

R9644

Ribavirin

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

Susan Barrett et al.
Antiviral research, 108, 30-35 (2014-05-24)
The influenza virus neuraminidase inhibitors are normally slow binding inhibitors, but many mutations leading to resistance, also result in the loss of the slow binding phenotype. Mutations can also affect the rate of dissociation of the inhibitors from the neuraminidase
Kristin A Gabor et al.
Disease models & mechanisms, 7(11), 1227-1237 (2014-09-06)
Seasonal influenza virus infections cause annual epidemics and sporadic pandemics. These present a global health concern, resulting in substantial morbidity, mortality and economic burdens. Prevention and treatment of influenza illness is difficult due to the high mutation rate of the
Alireza Eshaghi et al.
Antimicrobial agents and chemotherapy, 58(12), 7188-7197 (2014-09-24)
Immunocompromised patients are predisposed to infections caused by influenza virus. Influenza virus may produce considerable morbidity, including protracted illness and prolonged viral shedding in these patients, thus prompting higher doses and prolonged courses of antiviral therapy. This approach may promote
Xiaoli Xiong et al.
Virology, 456-457, 179-187 (2014-06-04)
Mutant H5N1 influenza viruses have been isolated from humans that have increased human receptor avidity. We have compared the receptor binding properties of these mutants with those of wild-type viruses, and determined the structures of their haemagglutinins in complex with
Ken Watanabe et al.
Archives of medical research, 45(5), 359-365 (2014-06-01)
Influenza viruses are a serious threat to human health and cause thousands of deaths annually. Thus, there is an urgent requirement for the development of novel anti-influenza virus drugs. Therefore, the aim of this study was to evaluate the anti-influenza
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique